IOVANCE COO RSUs vest; shares withheld for tax

IOVANCE BIOTHERAPEUTICS, INC.

Rhea-AI Filing Summary

IOVANCE BIOTHERAPEUTICS, INC. Chief Operating Officer Igor Bilinsky reported routine equity compensation activity. On the transaction date, 7,813 restricted stock units (RSUs) vested into shares of common stock, each RSU representing a right to receive one share. To cover mandatory tax withholding on this vesting, 3,976 shares of common stock were withheld by the company; this was explicitly not an open market sale. After these events, Bilinsky directly holds 133,920 shares of common stock and 54,691 RSUs from a March 5, 2025 grant, which are scheduled to vest in equal quarterly installments.

Insider Trade Summary

7,813 shares exercised/converted

Exercise 3 txns

Insider BILINSKY IGOR

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	7,813	$0.00	$0.00
Exercise	Common Stock	7,813	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	3,976	$4.23	$17K

Holdings After Transaction: Restricted Stock Units — 54,691 contracts (Direct); Common Stock — 133,920 shares (Direct)

Footnotes (6)

1. F1. Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
2. F2. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
3. F3. Represents common stock remaining after deducting the common stock withheld for taxes.
4. F4. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
5. F5. The remaining RSUs will vest in equal quarterly installments.
6. F6. Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person.

Key Figures

RSUs vested: 7,813 units Shares withheld for tax: 3,976 shares at $4.23 Shares held after transaction: 133,920 shares +3 more

6 metrics

RSUs vested 7,813 units Restricted Stock Units converting into common stock on transaction date

Shares withheld for tax 3,976 shares at $4.23 Common stock withheld to satisfy mandatory tax obligations

Shares held after transaction 133,920 shares Direct common stock holdings following tax withholding disposition

RSUs remaining 54,691 units Unvested RSUs from March 5, 2025 grant, vesting quarterly

RSU exercise price $0.00 per unit Conversion price for vested restricted stock units into common stock

Tax withholding shares summary 3,976 shares Total shares disposed as tax-withholding per transaction summary

Key Terms

Restricted Stock Units, mandatory tax withholding requirements, contingent right, derivative exercise/conversion, +1 more

5 terms

Restricted Stock Units financial

"security_title: "Restricted Stock Units""

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

mandatory tax withholding requirements financial

"to satisfy the mandatory tax withholding requirements upon vesting of the RSUs"

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's common stock."

derivative exercise/conversion financial

"transaction_action: "derivative exercise/conversion""

tax-withholding disposition financial

"transaction_action: "tax-withholding disposition""

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did IOVANCE (IOVA) COO Igor Bilinsky report?

IOVANCE COO Igor Bilinsky reported RSU vesting and related tax withholding. 7,813 restricted stock units converted into common shares, and 3,976 shares were withheld to satisfy mandatory tax obligations, with no open market sale involved.

Did the IOVANCE (IOVA) COO sell shares in the open market?

The filing states there was no open market sale. 3,976 shares of common stock were withheld by IOVANCE to satisfy mandatory tax withholding when RSUs vested, which is a compensation-related disposition rather than a discretionary market sale.

How many IOVANCE (IOVA) shares does the COO hold after this filing?

After the reported transactions, COO Igor Bilinsky directly holds 133,920 shares of IOVANCE common stock. This figure reflects his position following RSU vesting and the shares withheld to cover the associated tax obligations.

How many unvested RSUs does the IOVANCE (IOVA) COO still have?

Following the vesting event, Igor Bilinsky holds 54,691 remaining restricted stock units from a March 5, 2025 grant. These RSUs are scheduled to vest in equal quarterly installments, providing additional potential future shares over time.

What does the tax withholding transaction mean in the IOVANCE (IOVA) Form 4?

The tax withholding transaction reflects 3,976 shares withheld to meet mandatory tax requirements on RSU vesting. The filing clarifies this is a payment of tax liability using shares, not a voluntary open market sale of IOVANCE stock by the COO.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/09/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BILINSKY IGOR

(Last) (First) (Middle)

C/O IOVANCE BIOTHERAPEUTICS, INC.

825 INDUSTRIAL ROAD, SUITE 100

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	06/05/2026		M		7,813	A	$0	137,896	D
Common Stock(2)	06/05/2026		F		3,976	D	$4.23	133,920(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(4)	06/05/2026		M			7,813	(5)	(5)	Common stock	7,813	$0.00	54,691(6)	D

Explanation of Responses:

1. Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.

2. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.

3. Represents common stock remaining after deducting the common stock withheld for taxes.

4. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

5. The remaining RSUs will vest in equal quarterly installments.

6. Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person.

	/s/ Igor Bilinsky	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)